Clincosm LogoSign in Get a demo

DMR_NASH_001: Effect of DMR in the Treatment of NASH

Sponsor
Erasme University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03536650
Collaborator
Fractyl Laboratories, Inc. (Industry)
14
Enrollment
1
Location
1
Arm
37.7
Actual Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of metabolic syndrome and constitutes a serious public health concern manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease. Insuline resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing. Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH. Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications. The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.

Condition or Disease Intervention/Treatment Phase
  • Device: DMR
 N/A

Detailed Description

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of a metabolic syndrome and constitutes a serious public health concern, manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease.

Insulin resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing.

Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH.

Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications.

The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.

Design of study The study is designed as a single arm, proof of concept, non-randomized, open label trial to be conducted at one investigational site. All patients with biopsy proven NASH will undergo an upper endoscopy to perform a duodenal mucosal resurfacing procedure. Evolution of liver steatosis (assessed by MRI), insulin resistance (assessed by oral glucose tolerance test), liver damage (evaluated by blood tests), liver elastography (assessed by fibroscan, fibrotest), biometric parameters will be performed pre- and post-procedure.

Primary outcome :
  • Feasability and safety of duodenal mucosal resurfacing, using Revita ™ duodenal mucosal resurfacing after submucosal injection, in patients with NASH.
Secondary outcomes:

  • Evolution of steatosis assessed by MRI 6 months after the procedure.

  • Evolution of liver fibrosis (assessed by Fibroscan, Fibrotest, Fibrosis four score (FIB-4) and NAFLD fibrosis score) at 6 and 12 months after the procedure.

  • Evolution of liver tests at 6 and 12 months after the procedure.

  • Evolution of insulin resistance at 1,3,6 and 12 months after the procedure.

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study
Actual Study Start Date :
Nov 8, 2017
Actual Primary Completion Date :
Jul 15, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: DMR procedure

Device: DMR
Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study. Other Names: DMR Revita
Other Names:
  • Revita

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH. [12 months]

      Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants. Safety evaluations will also be performed to ensure no subsequent adverse events have occurred and to ensure any adverse events during the trial that are considered on-going are stable or have resolved. Safety will be assessed at 1 and 6 months following the intervention.

    Secondary Outcome Measures

    1. Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 6 months in DMR subjects. [baseline and 6 months post-procedure]

      Magnetic Resonance Fat fraction

    2. Change in NAS score from baseline in the following 12 months in DMR subjects. [baseline and 12 months post-procedure]

      Centrally scored histological improvement in NAFLD from baseline to the end of 12 months post-procedure, where improvement is defined as: No worsening in fibrosis; and A decrease in NAFLD Activity Score (NAS) of at least 2 points

    3. Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 6 months in DMR subjects [baseline and 6 months post-procedure]

      Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score <1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of >3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.

    4. Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 12 months in DMR subjects [baseline and 12 months post-procedure]

      Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score <1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of >3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.

    5. Change in Transient Elastography using Firboscan from baseline in the following at 6 months in DMR subjects [baseline and 6 months post-procedure]

      Transient Elastography

    6. Change in Transient Elastography using Firboscan from baseline in the following at 12 months in DMR subjects [baseline and 12 months post-procedure]

      Transient Elastography

    7. Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 12 months in DMR subjects. [baseline and 12 months post procedure]

      Magnetic Resonance Fat fraction

    8. Change in transaminases levels from baseline in the following 6 months in DMR subjects [baseline and 6 months post-procedure]

      Transaminases levels

    9. Change in transaminases levels from baseline in the following 12 months in DMR subjects [baseline and 12 months post-procedure]

      Transaminases levels

    10. Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 6 months in DMR subjects [baseline and 6 months post-procedure]

      Insulin resistance as abnormal HOMA IR

    11. Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 12 months in DMR subjects [baseline and 12 months post procedure]

      Insulin resistance as abnormal HOMA IR

    12. Change in stage of fibrosis from baseline in the following 12 months in DMR subjects [baseline and 12 months post-procedure]

      Liver histology

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    28 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Adult subjects (male and female), age 28 to 75 years.

    2. NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree> 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study and confirmed by central reading during the periode and (apendix 1)

    3. SAF (steatosis, activity, fibrosis) activity score of 3 or 4 (>2)

    4. SAF steatosis score ≥ 1

    5. SAF fibrosis score < 4

    6. No other causes of chronic liver disease and compensated liver disease.

    7. If applicable, have a type 2 diabetes with HbA1c <10.0 %

    8. BMI (body mass index) ≥ 24 and ≤ 40 kg/m2.

    9. Willing to sign an informed consent form.

    10. Willing to comply with study requirements

    Exclusion Criteria:

    1. Evidence of another cause of liver disease.

    2. History of sustained alcohol ingestion defined as: daily alcohol consumption > 30 g/day for males and > 20 g/day for females.

    3. Previous gastrointestinal surgery such as subjects who have had Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions.

    4. Known autoimmune disease, including celiac disease, or symptoms of systemic lupus eythematosus, sleroderma or other auto-immune connective tissue disorder.

    5. For type 2 diabetes subjects, no current use of insulin or GLP-1 analogues.

    6. Type 1 diabetes.

    7. Probable insulin production failure defined as fasting C peptide serum < 1 ng/ml.

    8. History of acute or chronic pancreatitis.

    9. Active malignancy.

    10. Persistent anemia defined as Hb < 10 g/dl.

    11. Use of anticoagulation therapy which cannot be discontinued for 7 days before and 14 days after the procedure.

    12. Use of P2Y12 inhibitors (clopidrogel, prasugrel, ticagrelor) which cannot be discontinued for 14 days before and14 days after the procedure.

    13. History of coagulopathy or upper gastro-intestinal bleeding conditions likely to bleed.

    14. Taking corticosteroids or drugs which possibly affect gastrointestinal motility or liver.

    15. Unable to discontinue NSAIDs (non-steroidal anti- inflammatory drugs) during the treatment up to 4 weeks after procedure.

    16. Use of weight loss medications.

    17. Presence of liver cirrhosis (defined by histology)

    18. Platelet count < 120 x 109/L.

    19. Clinical evidence of hepatic decompensation or severe liver impairment as defined by the presence of any of the following abnormalities:

    20. Serum albumin < 32 g/L.

    21. INR> 1.3.

    22. Direct bilirubin> 1.3 mg/L.

    23. ALT or AST > 5x ULN.

    24. Alkaline Phosphatase > 3x ULN.

    25. History of esophageal varices, ascites or hepatic encephalopathy.

    26. Splenomegaly.

    27. Human immunodeficiency virus.

    28. Contraindications to MRI as defined below.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Erasme Hospital Brussels Belgium 1070

    Sponsors and Collaborators

    • Erasme University Hospital
    • Fractyl Laboratories, Inc.

    Investigators

    • Principal Investigator: Jacques Deviere, PhD, MD, Erasme hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Erasme University Hospital
    ClinicalTrials.gov Identifier:
    NCT03536650
    Other Study ID Numbers:
    • P2017/302
    First Posted:
    May 25, 2018
    Last Update Posted:
    Feb 25, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Erasme University Hospital
    Metabolic diseases
    Additional relevant MeSH terms:
    Fatty Liver
    Non-alcoholic Fatty Liver Disease

    Study Results

    No Results Posted as of Feb 25, 2021